Vera Therapeutics Presents New Analysis of Phase 2a JANUS
New analysis of Phase 2a JANUS clinical trial showed atacicept reduced immune complex levels in patients with IgA nephropathy (IgAN)Atacicept is the first...
Source: globenewswire.com
Page 13 - Randomized Phase News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Randomized Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Randomized Phase Today - Breaking & Trending Today
Legend Biotech Shares Updated Data from Comprehensive Cilta-Cel Clinical Development Program at ASH
Seven accepted poster presentations showcase our continued leadership in CAR-T cell therapy research for patients with multiple myelomaNew analysis of sustained minimal residual disease (MRD) negativity from the pivotal CARTITUDE-1 study of CARVYKTI® (ciltacabtagene autoleucel, cilta-cel) in heavily pretreated adult...
Source: pharmiweb.com
More than 50 Abstracts from Incyte's Robust Oncology Portfolio to be Featured at the 64th ASH Annual Meeting
- Plenary Scientific Session to highlight Incyte-discovered novel anti-mutant CALR-targeted monoclonal antibody INCA033989 - Data from three of the Company's LIMBER studies evaluating ruxolitinib
Source: finanznachrichten.de
Bausch Health Companies Inc: Ortho Dermatologics to Present New Data at the 2022 Innovations in Dermatology Conference
Nine Poster Presentations Include New Analyses of SILIQ® and JUBLIA®LAVAL, QC / ACCESSWIRE / November 1, 2022 / - Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health") and its dermatology
Source: finanznachrichten.de
Atossa Therapeutics, Inc. Receives Authorization from FDA
Atossa to begin Phase 2 Study of (Z)-endoxifen in 4th Quarter...
Source: globenewswire.com